Inspiring innovative biotherapeutic drug development at PEGS 2019

One year on from introducing the AQS3pro, a powerful new protein characterization solution, we demonstrated compelling new application data and significant endorsements from leading biopharmaceutical companies at PEGS 2019. Driven by industry-leading AQS3delta analytical software, the AQS3pro is transforming the utility of IR spectroscopy for the analysis of protein structure, delivering high sensitivity results in substantially streamlined workflows.

With the structure of therapeutic proteins essential to their efficacy and safety, accurate and repeatable measurements are required from the earliest stages of drug development to commercial manufacture, highlighting the importance of our Microfluidic Modulation Spectroscopy technique. We presented a poster at the conference, on the analysis of a monoclonal antibody in two different buffers using Microfluidic Modulation Spectroscopy featuring data from Celldex.

To request a copy of the poster, please contact info@redshiftbio.com.